GC Cell Presents Study Results on ImmunCell-LC Injection in Liver Transplant Patients at SISSO

by Kwak Minjae

Published 10 Feb.2026 13:44(KST)

GC Cell announced on the 10th that on February 7 it presented the results of a study of ImmunCell-LC Injection in liver transplant patients at the 2026 Seoul International Symposium of Surgical Oncology (SISSO).

Jissisel presented the results of a study on Imyunselselssuju in liver transplant patients at SISSO. Jissisel

This retrospective study compared treatment outcomes between a patient group that received ImmunCell-LC Injection and a group that did not receive any additional treatment, targeting liver transplant patients who exceeded the Milan criteria. According to GC Cell, the 2-year recurrence-free survival rate in the group treated with ImmunCell-LC Injection was 87.5%, which was clearly higher than that of the control group (62.9%). During the same period, the overall survival rate in the treatment group was also 100%, showing a significant difference compared to the control group (81.5%).

Notably, rejection after transplantation did not increase even in a setting where immunosuppressants were used in combination. GC Cell explained that, in liver transplant patients, there had been considerable concern that immunotherapy could trigger long-term graft rejection, but in this analysis there was no significant difference in the incidence of rejection between the treatment and control groups. This is interpreted to mean that ImmunCell-LC Injection demonstrated the ability to maintain antitumor efficacy while also preserving a balance in immune responses.

In addition, no clear deterioration in liver function parameters was observed during the treatment period, leading to the assessment that its safety as an applicable adjuvant anticancer therapy for liver transplant patients was also confirmed. GC Cell stated that through this retrospective analysis, ImmunCell-LC Injection once again demonstrated its potential to be used as a treatment option to suppress cancer recurrence not only after conventional liver resection or local therapy, but also in the challenging treatment setting of liver transplantation.

Professor Hong Geun, Director of the Organ Transplantation Center at Ewha Womans University Seoul Hospital, said, "For liver transplant patients, when immunosuppressants are used, if cancer recurs after transplantation, treatment becomes extremely difficult because of reduced immunity and the risk of rejection," adding, "This study is meaningful in that it shows ImmunCell-LC Injection can provide a starting point for treatment in such situations."

Moon Jongsik, Head of the Oncology Division at GC Cell, said, "We will continue to expand the clinical applicability of ImmunCell-LC Injection in the field of adjuvant therapy for hepatocellular carcinoma so that we can help improve treatment environments for patients in the future."